Leiv Lea - 11 Aug 2022 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Role
Chief Financial Officer
Signature
/s/ Leiv Lea
Issuer symbol
CRVS
Transactions as of
11 Aug 2022
Net transactions value
$0
Form type
4
Filing time
15 Aug 2022, 18:49:39 UTC
Previous filing
17 Mar 2022
Next filing
15 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Stock Option (Right to Buy) Award $0 +160,000 $0.000000 160,000 11 Aug 2022 Common Stock 160,000 $0.9650 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from August 11, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.